Sun Pharmaceutical to acquire Checkpoint Therapeutics for $355 million, with potential additional payment.

From Nasdaq: 2025-03-09 22:47:29

Sun Pharmaceutical Industries Limited has agreed to acquire Checkpoint Therapeutics Inc. for an upfront cash payment of $4.10 per share, totaling up to $355 million. Checkpoint focuses on developing treatments for solid tumor cancers and has FDA approval for UNLOXCYT. The deal includes a contingent value right of up to $0.70 per share if cosibelimab is approved in the EU or certain key countries. The transaction is expected to close in the second quarter of 2025, with Fortress Biotech, Checkpoint’s controlling stockholder, agreeing to vote in favor of the deal.



Read more at Nasdaq: Sun Pharmaceutical Industries Agrees To Acquire Checkpoint Therapeutics